Special Issue

The Use of Epigenetic Biomarkers as Diagnostic and Therapeutic Options 2.0

Message from the Guest Editor

The present Special Issue aims to publish high-quality research articles as well as review contributions on a variety of topics related to epigenetic biomarkers, COVID-19, and therapeutic options. Potential topics include, but are not limited to:

- Types of epigenetic biomarkers used in clinical practice for different diseases:
  - DNA methylation of circulating or non-circulating DNA;
  - Histone modification (e.g., histone methylation and acetylation);
  - microRNA, circular RNA, and other non-coding RNA;
- Methods of new epigenetic biomarker discovery;
- The potential of liquid biopsy for epigenetic biomarker detection;
- The process of developing of epigenetic biomarkers as treatment options for clinical practice.

Guest Editor

Dr. Yuen Yee Cheng

Institute for Biomedical Materials and Devices, University of Technology Sydney, 15 Broadway, Ultimo, NSW 2007, Australia

Deadline for manuscript submissions

closed (30 April 2022)

Epigenomes

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed

mdpi.com/si/78373

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

mdpi.com/journal/epigenomes

Epigenomes

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed

mdpi.com/journal/epigenomes

MDPI

About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.
Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione
Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).